Researchers Advance New Therapy with Potential Benefit for Underserved Patients with Lung and Ovarian Cancers

In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers from The University of Texas MD Anderson Cancer Center's Therapeutics Discovery division and Ipsen Biopharmaceuticals reported the preclinical discovery and early-stage clinical development of this novel drug. IPN60090, now under investigation in a Phase I trial, may hold benefit for certain patients with lung and ovarian cancers.
from Medical Xpress - latest medical and health news stories https://ift.tt/3aIgiWu